This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
27 - 29 May, 2026
Congress CenterBasel Switzerland

Anette Sommer, PhD
Head of Bioconjugates Research at Lonza Advanced Synthesis – R&D at Synaffix BV
Speaker

Profile

Anette Sommer is the Head of Bioconjugates Research at Lonza Advanced Synthesis – R&D. She was the Emerging Science & Innovation Lead (ESL) Oncology Europe at Pfizer. In this role, she was responsible for search and evaluation of novel preclinical stage opportunities and technologies for cancer therapies in Europe. Prior to joining Pfizer, Anette held several positions in drug discovery at Schering AG and Bayer AG, Berlin, Germany – covering all stages of the R&D value chain and with a focus on antibody-drug conjugates and radioconjugates. Anette is co-author of >50 scientific publications and >10 patent applications.

Agenda Sessions

  • Chairwoman's Remarks

    14:00
  • Advantages of GlycoConnect® Platform Technology – Clinical Insights and toxSYN® Platform Expansion

    09:20